MariaLiaPalombaMD

PubMed

• Metabolic Tumor Volume Response after Bridging Therapy Determines Chimeric Antigen Receptor T-Cell Outcomes in Large B-Cell Lymphoma.
  Harper Hubbeling, Doris Leithner, Emily A Silverman, Jessica Flynn, Sean Devlin
  Clinical Cancer Research. 2024-11-15
• Anti-CD19 chimeric antigen receptor T-cell therapy has less efficacy in Richter transformation than in <I>de novo</I> large B-cell lymphoma and transformed low-grade B...
  Ohad Benjamini, Shalev Fried, Roni Shouval, Jessica R Flynn, Ofrat Beyar-Katz
  Haematologica. 2024-11-01
• 1 citations
  CNS bridging radiotherapy achieves rapid cytoreduction before CAR T-cell therapy for aggressive B-cell lymphomas.
  Gustav Y Cederquist, Javin Schefflein, Sean M Devlin, Gunjan L Shah, Roni Shouval
  Blood Advances. 2024-10-08

Journal Articles

• Phase 3 Trial of Ibrutinib plus Rituximab in Waldenström’s Macroglobulinemia  
  Jeffrey V Matous, M Lia Palomba, Steven P Treon, The New England Journal of Medicine

Abstracts/Posters

• Outpatient Treatment with Lisocabtagene Maraleucel (liso-cel) in Three Ongoing Clinical Studies in Relapsed/Refractory (R/R) B Cell Non-Hodgkin Lymphoma (NHL), Includi...
  Maria Lia Palomba, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Comparing Gradings of Immune Effector Cells Toxicities: Application of Astct Consensus Grading System and Implications for Clinical Management
  Maria Lia Palomba, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Pivotal Safety and Efficacy Results from Transcend NHL 001, a Multicenter Phase 1 Study of Lisocabtagene Maraleucel (liso-cel) in Relapsed/Refractory (R/R) Large B Cel...
  Maria Lia Palomba, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Impact and Safety of Chimeric Antigen Receptor T Cell Therapy in Vulnerable Older Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma
  Maria Lia Palomba, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Easix and Modified-Easix Are Early Predictors of Severe Cytokine Release Syndrome and Neurotoxicity in Patients Treated with Chimeric Antigen Receptor T Cells
  Maria Lia Palomba, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• A Pilot Study of Brentuximab Vedotin Combined with AVD Chemotherapy and Radiotherapy in Patients with Newly Diagnosed Early Stage, Unfavorable Risk Hodgkin Lymphoma
  Maria Lia Palomba, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Join now to see all

Lectures

• Fast and Furious Cars: Looking Ahead to Next-Generation Treatments and New Combinations 
  ASCO Annual Meeting 2019 - Chicago, IL - 6/1/2019
• Atezolizumab in Combination with Obinutuzumab and Lenalidomide Demonstrates Favorable Activity and Manageable Toxicity in Patients with Relapsed/Refractory Follicular ... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• A Phase I First-in-Human Clinical Trial of CD19-Targeted 19-28z/4-1BBL “Armored” CAR T Cells in Patients with Relapsed or Refractory NHL and CLL Including Richter's Tr... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Ibrutinib Treatment in Waldenström’s Macroglobulinemia: Follow-up Efficacy and Safety from the iNNOVATETM Study 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Ibrutinib for the Treatment of Bing-Neel Syndrome 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Join now to see all